Narrative review / 2012
Curcumin co-administered with conventional drugs was reported to be well-tolerated and effective for maintaining remission in ulcerative colitis.
This review examines preclinical and clinical observations regarding curcumin, an active component of turmeric, for inflammatory bowel disease (IBD) such as ulcerative colitis. Preclinical studies indicate curcumin prevents or ameliorates colitis and inflammation by targeting free radicals, kinases, myeloperoxidase, inflammatory mediators, and NF-κB. Clinical studies showed that co-administration of curcumin with conventional drugs was well-tolerated, safe, and effective for maintaining remission, preventing relapse, and improving clinical activity index. The authors note that large randomized controlled clinical trials are still required.
- Study type
- Narrative review of preclinical and clinical studies
- Who was studied
- Patients with inflammatory bowel disease / ulcerative colitis and animal models
- What was measured
- Prevention, amelioration of colitis, remission maintenance, and clinical index
THE PAPER
Curcumin, an active component of turmeric in the prevention and treatment of ulcerative colitis: preclinical and clinical observations.
Baliga MS, Joseph N, Venkataranganna MV, Saxena A, Ponemone V, Fayad R. Food Funct, 2012.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.